Triplet Therapy with Palbociclib, Taselisib, and Fulvestrant in <i>PIK3CA</i> -Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
Javier Pascual(Breast Cancer Now), Nicholas C. Turner(Institute of Cancer Research), Karen E. Swales(Institute of Cancer Research), Paula Proszek(BMW (Germany)), Mona Parmar(Institute of Cancer Research), Isaac García-Murillas(Breast Cancer Now), Alison Turner(Institute of Cancer Research), Joline S.J. Lim(National University Cancer Institute, Singapore), Michael Hubank(Royal Marsden Hospital), Iain R. Macpherson(Beatson West of Scotland Cancer Centre), Heidrun Gevensleben(University Hospital Bonn), Alex Pearson(Breast Cancer Now), Jenny King(Institute of Cancer Research), María Teresa Herrera-Abreu(Institute of Cancer Research), Laura Finneran(Institute of Cancer Research), Rosalind Cutts(Breast Cancer Now), Toby Prout(Institute of Cancer Research), Anne Armstrong(The Christie NHS Foundation Trust), Sarah Hrebien(Breast Cancer Now), Florence I. Raynaud(Institute of Cancer Research), Ruth Ruddle(Institute of Cancer Research), Emma Hall(Institute of Cancer Research), Juanita Lopez(Institute of Cancer Research), Alicia Okines(Royal Marsden NHS Foundation Trust), Timothy A. Yap(The University of Texas MD Anderson Cancer Center), Jason Malia(Institute of Cancer Research), Margaret Hills(Royal Marsden NHS Foundation Trust), Alistair Ring(National Health Service)
Cited by 67
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer
|New England Journal of Medicine|2018|1.3k